This inventor holds 6 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Medimmune Limited. Active years: 2016-2021.
Location History:
- Boyds, MD (US) (2016 - 2017)
- Gaithersburg, MD (US) (2018 - 2021)
Company Filing History:
Years Active: 2016-2021
Title: Ambarish Shah: Innovator in Polypeptide Purification
Introduction
Ambarish Shah is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biochemistry, particularly in the purification of active polypeptides and immunoconjugates. With a total of 6 patents to his name, Shah's work has advanced the understanding and application of these important biological molecules.
Latest Patents
One of Shah's latest patents is a method for purifying active polypeptides or immunoconjugates. This invention provides methods for isolating an active polypeptide or immunoconjugate by purifying a solution that contains both the active polypeptide or immunoconjugate and an acidic variant, such as a deamidated variant. The purification process utilizes anion exchange chromatography, which enhances the efficiency of isolating the desired compounds. Additionally, the invention includes compositions, formulations, and unit dosage forms that comprise the purified polypeptide or immunoconjugate.
Career Highlights
Ambarish Shah is currently employed at MedImmune Limited, where he continues to innovate in the field of biopharmaceuticals. His work at MedImmune has allowed him to collaborate with other experts in the field and contribute to the development of new therapeutic solutions.
Collaborations
Shah has worked alongside notable colleagues such as Thomas Linke and William K Wang. These collaborations have further enriched his research and development efforts, leading to advancements in the purification processes of biopharmaceuticals.
Conclusion
Ambarish Shah's contributions to the field of polypeptide purification are significant and impactful. His innovative methods and collaborative efforts at MedImmune Limited continue to push the boundaries of biochemistry and biopharmaceutical development.